154 related articles for article (PubMed ID: 22481485)
21. Dynamics of Aβ42 reduction in plasma, CSF and brain of rats treated with the γ-secretase modulator, GSM-10h.
Hawkins J; Harrison DC; Ahmed S; Davis RP; Chapman T; Marshall I; Smith B; Mead TL; Medhurst A; Giblin GM; Hall A; Gonzalez MI; Richardson J; Hussain I
Neurodegener Dis; 2011; 8(6):455-64. PubMed ID: 21389687
[TBL] [Abstract][Full Text] [Related]
22. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.
Georgievska B; Gustavsson S; Lundkvist J; Neelissen J; Eketjäll S; Ramberg V; Bueters T; Agerman K; Juréus A; Svensson S; Berg S; Fälting J; Lendahl U
J Neurochem; 2015 Feb; 132(4):477-86. PubMed ID: 25156639
[TBL] [Abstract][Full Text] [Related]
23. Orally bioavailable and brain-penetrant pyridazine and pyridine-derived γ-secretase modulators reduced amyloidogenic Aβ peptides in vivo.
Huang Y; Li T; Eatherton A; Mitchell WL; Rong N; Ye L; Yang XJ; Jin S; Ding Y; Zhang J; Li Y; Wu Y; Jin Y; Sang Y; Cheng Z; Browne ER; Harrison DC; Hussain I; Wan Z; Hall A; Lau LF; Matsuoka Y
Neuropharmacology; 2013 Jul; 70():278-86. PubMed ID: 23485401
[TBL] [Abstract][Full Text] [Related]
24. gamma-Secretase as a therapeutic target in Alzheimer's disease.
Guardia-Laguarta C; Pera M; Lleó A
Curr Drug Targets; 2010 Apr; 11(4):506-17. PubMed ID: 20015011
[TBL] [Abstract][Full Text] [Related]
25. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
26. Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein.
Yang T; Arslanova D; Gu Y; Augelli-Szafran C; Xia W
Mol Brain; 2008 Nov; 1():15. PubMed ID: 18983676
[TBL] [Abstract][Full Text] [Related]
27. BACE inhibition-dependent repair of Alzheimer's pathophysiology.
Keskin AD; Kekuš M; Adelsberger H; Neumann U; Shimshek DR; Song B; Zott B; Peng T; Förstl H; Staufenbiel M; Nelken I; Sakmann B; Konnerth A; Busche MA
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):8631-8636. PubMed ID: 28739891
[TBL] [Abstract][Full Text] [Related]
28. Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for Abeta production inhibitors.
El Mouedden M; Vandermeeren M; Meert T; Mercken M
Curr Pharm Des; 2006; 12(6):671-6. PubMed ID: 16472156
[TBL] [Abstract][Full Text] [Related]
29. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.
Best JD; Smith DW; Reilly MA; O'Donnell R; Lewis HD; Ellis S; Wilkie N; Rosahl TW; Laroque PA; Boussiquet-Leroux C; Churcher I; Atack JR; Harrison T; Shearman MS
J Pharmacol Exp Ther; 2007 Feb; 320(2):552-8. PubMed ID: 17099072
[TBL] [Abstract][Full Text] [Related]
30. Interplay between α-, β-, and γ-secretases determines biphasic amyloid-β protein level in the presence of a γ-secretase inhibitor.
Ortega F; Stott J; Visser SA; Bendtsen C
J Biol Chem; 2013 Jan; 288(2):785-92. PubMed ID: 23152503
[TBL] [Abstract][Full Text] [Related]
31. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
32. Cisterna magna cannulated repeated CSF sampling rat model--effects of a gamma-secretase inhibitor on Aβ levels.
Shapiro JS; Stiteler M; Wu G; Price EA; Simon AJ; Sankaranarayanan S
J Neurosci Methods; 2012 Mar; 205(1):36-44. PubMed ID: 22226743
[TBL] [Abstract][Full Text] [Related]
33. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.
Portelius E; Van Broeck B; Andreasson U; Gustavsson MK; Mercken M; Zetterberg H; Borghys H; Blennow K
J Alzheimers Dis; 2010; 21(3):1005-12. PubMed ID: 20634579
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic potential of gamma-secretase inhibitors and modulators.
Imbimbo BP
Curr Top Med Chem; 2008; 8(1):54-61. PubMed ID: 18220933
[TBL] [Abstract][Full Text] [Related]
35. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease.
Blain JF; Bursavich MG; Freeman EA; Hrdlicka LA; Hodgdon HE; Chen T; Costa DE; Harrison BA; Kapadnis S; Murphy DA; Nolan S; Tu Z; Tang C; Burnett DA; Patzke H; Koenig G
Alzheimers Res Ther; 2016 Aug; 8(1):34. PubMed ID: 27572246
[TBL] [Abstract][Full Text] [Related]
36. Modulation of γ-secretase activity by multiple enzyme-substrate interactions: implications in pathogenesis of Alzheimer's disease.
Svedružić ZM; Popović K; Smoljan I; Sendula-Jengić V
PLoS One; 2012; 7(3):e32293. PubMed ID: 22479317
[TBL] [Abstract][Full Text] [Related]
37. Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data.
Niva C; Parkinson J; Olsson F; van Schaick E; Lundkvist J; Visser SA
Eur J Clin Pharmacol; 2013 Jun; 69(6):1247-60. PubMed ID: 23288352
[TBL] [Abstract][Full Text] [Related]
38. The Role of Secretase Pathway in Long-term Brain Inflammation and Cognitive Impairment in an Animal Model of Severe Sepsis.
Michelon C; Michels M; Abatti M; Vieira A; Borges H; Dominguini D; Barichello T; Dal-Pizzol F
Mol Neurobiol; 2020 Feb; 57(2):1159-1169. PubMed ID: 31701437
[TBL] [Abstract][Full Text] [Related]
39. The β-secretase (BACE) inhibitor NB-360 in preclinical models: From amyloid-β reduction to downstream disease-relevant effects.
Neumann U; Machauer R; Shimshek DR
Br J Pharmacol; 2019 Sep; 176(18):3435-3446. PubMed ID: 30657591
[TBL] [Abstract][Full Text] [Related]
40. Auraptene increases the production of amyloid-β via c-Jun N-terminal kinase-dependent activation of γ-secretase.
Jung CG; Uhm KO; Horike H; Kim MJ; Misumi S; Ishida A; Ueda Y; Choi EK; Kim YS; Michikawa M; Hida H
J Alzheimers Dis; 2015; 43(4):1215-28. PubMed ID: 25147119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
